Stock Events

Stock Events

Kodiak Sciences 

€37.74
0
+€2.08+5.83% Today

Statistics

Day High
38.62
Day Low
37.74
52W High
38.62
52W Low
1.99
Volume
0
Avg. Volume
167
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q4 2025
Next
-0.91
-0.88
-0.84
-0.81
Expected EPS
-0.80986500098
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow K27.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals competes directly with Kodiak Sciences in the development of treatments for retinal diseases, including age-related macular degeneration.
Regenxbio
RGNX
Mkt Cap454.19M
REGENXBIO Inc. is a competitor because it also focuses on gene therapy for retinal diseases, a key area of focus for Kodiak Sciences.
Bausch Health Companies
BHC
Mkt Cap2.09B
Bausch Health Companies, through its eye health division, competes in the broader ophthalmology market, impacting Kodiak Sciences' market share.
Novartis
NVS
Mkt Cap297.35B
Novartis AG is a major pharmaceutical company with a strong presence in the ophthalmology sector, including treatments for conditions that Kodiak Sciences targets.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie, after acquiring Allergan, has become a significant player in the eye care market, competing with Kodiak Sciences in several areas.
GSK
GSK
Mkt Cap116.3B
GlaxoSmithKline plc has investments in healthcare treatments that span a wide range, including ophthalmology, indirectly competing with Kodiak Sciences.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc., as a large pharmaceutical company, has interests in developing treatments for various diseases, including those in the eye care segment, posing competition to Kodiak Sciences.

About

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Show more...
CEO
Dr. Victor Perlroth M.D.
Employees
109
Country
United States
ISIN
US50015M1099

Listings

STU
DE
K27.STU
MU
DE
K27.MU
BOATS
BOATS
KOD.BOATS
XNAS
US
KOD

0 Comments

Share your thoughts

FAQ

What is Kodiak Sciences stock price today?▼
The current price of K27.STU is €37.74 EUR — it has increased by +5.83% in the past 24 hours. Watch Kodiak Sciences stock price performance more closely on the chart.
What is Kodiak Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kodiak Sciences stocks are traded under the ticker K27.STU.
Is Kodiak Sciences stock price growing?▼
K27.STU stock has risen by +8% compared to the previous week, the month change is a +93.29% rise, over the last year Kodiak Sciences has showed a +1,831% increase.
When is the next Kodiak Sciences earnings date?▼
Kodiak Sciences is going to release the next earnings report on May 20, 2026.
What were Kodiak Sciences earnings last quarter?▼
K27.STU earnings for the last quarter are -0.9 EUR per share, whereas the estimation was -0.91 EUR resulting in a +1.25% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Kodiak Sciences have?▼
As of April 15, 2026, the company has 109 employees.
In which sector is Kodiak Sciences located?▼
Kodiak Sciences operates in the Health & Wellness sector.
When did Kodiak Sciences complete a stock split?▼
Kodiak Sciences has not had any recent stock splits.
Where is Kodiak Sciences headquartered?▼
Kodiak Sciences is headquartered in Palo Alto, United States.